Thirty-three states have reached a settlement with Aventis and Ferring, two pharmaceutical companies, for delaying the entry of the generic for DDAVP (desmopressin). Barr Laboratories, the manufacturer of the generic, allegedly had its sales delayed because of materially misleading statements Aventis and Ferring made to the U.S. Patent Office.
Source: LegalNewsline
Related content: Whistling Past the Graveyard: The Problem with the Per Se Legality Treatment of Pay-For-Delay Settlements (Michael Kades, U.S. Federal Trade Commission)
Featured News
FTC Takes On Prescription Drug Middlemen Over High Insulin Costs
Sep 20, 2024 by
CPI
EU’s Incoming Competition Head Pushes for Policy Shift to Support ‘European Champions
Sep 19, 2024 by
CPI
Google Challenges $217 Million Legal Fee Demand in Privacy Case
Sep 19, 2024 by
CPI
EU Moves to Enforce Apple’s Compliance with New Market Rules
Sep 19, 2024 by
CPI
California Attorney General Bonta Stands Firm Against Albertsons-Kroger Merger
Sep 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
Francisco Javier Núñez Melgoza
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
Julio Garcia
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
Alejandra Palacios Prieto
The Cost of Making COFECE Disappear
Sep 3, 2024 by
Mateo Fernández